|Mr. Steven W. King||Pres, CEO & Director||873.31k||N/A||53|
|Mr. Paul J. Lytle CPA||Chief Financial Officer||597.92k||N/A||49|
|Mr. Mark R. Ziebell J.D.||VP, Gen. Counsel & Corp. Sec.||518.16k||N/A||53|
|Dr. Shelley P. M. Fussey Ph.D.||VP of Intellectual Property||365.15k||N/A||51|
|Mr. Joseph S. Shan M.P.H.||VP of Clinical & Regulatory Affairs||447.78k||N/A||44|
Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops monoclonal antibodies for the treatment of cancer in the United States. Its lead immunotherapy candidate is bavituximab, a monoclonal antibody that targets and binds to phosphatidylserine. The company also provides integrated current good manufacturing practices services from cell line development to commercial bio manufacturing for its third-party customers. In addition, its services comprise cGMP clinical and commercial manufacturing utilizing stainless steel and single use bioreactor technology, purification, bulk packaging, stability testing, regulatory strategy, and support. The company has license agreements with the University of Texas Southwestern Medical Center at Dallas; Genentech, Inc.; Avanir Pharmaceuticals, Inc.; and Lonza Biologics, as well as collaboration agreement with National Comprehensive Cancer Network, AstraZeneca PLC, and Memorial Sloan Kettering Cancer Center. Peregrine Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Tustin, California.
Peregrine Pharmaceuticals, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 7; Compensation: 8.